A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

BACKGROUND: Osimertinib is an effective first-line therapy option for EGFR-mutant NSCLC, but virtually all patients develop resistance. CRIPTO, through Src activation, has been implicated in resistance to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. Dasatinib, a Src inhibitor, has shown precli...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chul, Liu, Stephen V., Crawford, Jennifer, Torres, Tisdrey, Chen, Vincent, Thompson, Jillian, Tan, Ming, Esposito, Giuseppe, Subramaniam, Deepa S., Giaccone, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457399/
https://www.ncbi.nlm.nih.gov/pubmed/34568058
http://dx.doi.org/10.3389/fonc.2021.728155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457399/
https://www.ncbi.nlm.nih.gov/pubmed/34568058
http://dx.doi.org/10.3389/fonc.2021.728155

Ejemplares similares